Document Detail

Aliskiren: the first direct renin inhibitor available for clinical use.
MedLine Citation:
PMID:  21786226     Owner:  NLM     Status:  Publisher    
The idea of blocking the renin-angiotensin system (RAS) with the inhibition of the enzymatic activity of renin has been pursued for half a century, but it became a reality only recently, with the synthesis of aliskiren, the first direct renin inhibitor available for clinical use. The upstream blockade of the system induced by aliskiren, in combination with its unique pharmacological properties (inhibiting potency, high plasma concentration, long half-life and preferential partitioning in the kidney) makes this compound the ideal tool to achieve a complete blockade of the RAS. Consistent with expectations, present evidence indicates that aliskiren, at the licensed dosages of 150-300 mg/day, lowers blood pressure to the same extent as other first-line antihypertensive agents, with the additional advantage of a longer duration of action which persists for several days after the cessation of treatment. Moreover, aliskiren was found to act synergically not only with diuretics but also with other drug classes, including angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. In addition, results of recent clinical trials have shown that aliskiren possesses cardiovascular and renal protective properties which may contribute to the beneficial effects of this drug beyond the reduction of blood pressure. Finally, aliskiren has an excellent, placebo-like tolerability profile, a feature which is very relevant for improving compliance of patients.
Alberto Morganti; Chiara Lonati
Related Documents :
12190756 - Calf compartment pressures in the lloyd-davies position: a cause for concern?
1418206 - Intraarticular pressures in a gravity-fed arthroscopy fluid delivery system.
22810916 - Pressure-induced phase transitions in l-alanine, revisited. corrigendum.
21883196 - Migraine misdiagnosed as idiopathic intracranial hypertension.
25212496 - A new surgical triple procedure in pseudoexfoliation glaucoma using cataract surgery, t...
1888046 - The effect of intrathecal morphine on somatosensory evoked potentials in awake humans.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-12
Journal Detail:
Title:  Journal of nephrology     Volume:  -     ISSN:  1724-6059     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-7-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9012268     Medline TA:  J Nephrol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Internal Medicine and Hypertension Center, San Giuseppe Hospital, University of Milan, Milan - Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  p-Aminophenol and p-paraphenylenediamine induce injury and apoptosis of human HK-2 proximal tubular ...
Next Document:  What would we like to know, and what do we not know about fibroblast growth factor 23?